|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Translation initiation inhibitor rocaglates have been identified as the most potent drugs in MYC-driven lymphomas as they efficiently inhibit MYC expression and tumor cell viability.
|
31171817 |
2020 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
There were 14 cases (14.29%, 14/98) and 34 cases (34.70%, 34/98) of lymphomas with the DHL and DEL of MYC and BCL2/BCL6, respectively.
|
31615842 |
2020 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Patients with abdominal nodal disease had inferior lymphoma specific survival (p=0.04) and presented with higher age adjusted IPI (p<0.001), lactate dehydrogenase (p<0.001) and more often advanced stage (p<0.001), bulky disease (p<0.001), B-symptoms (p<0.001), and double expression of MYC and BCL2 (p=0.02) compared to patients without nodal abdominal involvement, but less often extranodal involvement (p<0.02).
|
31785002 |
2020 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
However, APE1 is unexpectedly dispensable for SHM in the S region and translocation between immunoglobulin heavy chain (IgH) and c-myc genes in the mouse B lymphoma cell line, CH12F3-2A.
|
30877298 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Lastly, high-intensity chemotherapy (either dose-adjusted rituximab and etoposide-prednisone-vincristine-cyclophosphamide-doxorubicin or rituximab and hyperfractionated cyclophosphamide-vincristine-doxorubicin-dexamethasone treatment) did not improve survival in patients with MYC-EC and MYC-rearranged lymphoma when compared with rituximab-cyclophosphamide-hydroxydaunomycin-vincristine-prednisone therapy.
|
30496802 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we review our current knowledge about the role of MYC in germinal center B-cells and lymphomas, discuss MYC-induced dependencies that can sensitize cancer cells to select pharmacological inhibitors, and illustrate their therapeutic potential in aggressive lymphomas-and in particular in DHL, in combination with BCL2 inhibitors.
|
30874346 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Identification of "Double Hit" Lymphomas Using Updated WHO Criteria: Insights From Routine MYC Immunohistochemistry in 272 Consecutive Cases of Aggressive B-Cell Lymphomas.
|
29629947 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
For a diagnosis of malignant lymphoma, it is important to confirm the presence or absence of MYC translocation and communicate these results to a clinical audience.
|
30448222 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Our analysis provided a novel look on the transition range between FL and DLBCL, on DLBCL with poor prognosis showing expression patterns resembling that of Burkitt's lymphoma and particularly on 'double-hit' MYC and BCL2 transformed lymphomas.
|
31039827 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of SMYD2 was validated in vivo but the functional analysis was constrained by in vitro loss of p53 in RUNX2/MYC lymphoma cell lines.
|
31257681 |
2019 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma.
|
31142587 |
2019 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Double/triple-hit lymphomas (DHL/THL) account for 5-10% of diffuse large B cell lymphoma (DLBCL) with rearrangement of MYC and BCL2 and/or BCL6 resulting in MYC overexpression.
|
31288832 |
2019 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, CD38<sup>bright</sup> may be a better indicator for predicting DH/THL-BCL2 than DHL-BCL6, and very bright CD38 expression was exclusive to MYC rearranged lymphomas.
|
30734478 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Loss of one allele of KAT6A extends the median survival of mice with MYC-induced lymphoma from 105 to 413 days<sup>11</sup>.
|
30069049 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The bivariate classifier was compared with 2 other MYC IHC classifiers (based on percentage of MYC IHC positive nuclei), all tested on 113 lymphomas including mostly diffuse large B-cell lymphomas with known MYC fluorescent in situ hybridization (FISH) status.
|
27093450 |
2018 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Optimal strategies have not been well defined for diagnosis of high grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBLwR) and double expressor lymphomas with MYC and BCL2 protein overexpression.
|
28868942 |
2018 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
CD16/CD56 expression without CD38<sup>higher</sup> and the lack of CD16/CD56 with CD38<sup>higher</sup> expression proves to be a reliable, fast, and cost-effective method for diagnosing 11q aberration and MYC rearrangements in CD10(+) aggressive lymphomas, respectively.
|
29327714 |
2018 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Double-hit lymphoma (DHL) is defined as lymphoma with concurrent BCL2 and MYC translocations.
|
29310838 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The phosphatidylinositol 3 kinase (PI3K)-glycogen synthase kinase β (GSK3β) axis plays a central role in MYC-driven lymphomagenesis, and MYC targeting with bromodomain and extraterminal protein family inhibitors (BETi) is a promising treatment strategy in lymphoma.
|
30134175 |
2018 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, we identified STAT-mediated BATF3 expression that is essential for lymphoma cell survival and promoted MYC activity in cHL and ALCL, hence we recognized a new oncogenic axis in these lymphomas.
|
28659618 |
2018 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Lymphomas with MYC and either BLC2 or BCL6 rearrangements or MYC and BCL-2 protein overexpression, classified as double-hit (DHL) or double-expressor (DEL) lymphomas, respectively, are associated with poorer response to standard immunochemotherapy.
|
29722657 |
2018 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this review, we summarize two sessions dedicated to "high-grade B cell lymphomas, with MYC and BCL2 and/or BCL6 rearrangements (so-called double/triple-hit lymphomas)" and "high-grade B cell lymphomas, NOS" as defined in the 2016 update of the WHO lymphoma classification, Burkitt lymphoma and related neoplasms, and terminally differentiated aggressive B cell lymphomas.
|
28844114 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The latest revision of lymphoma's World Health Organization classification describes the new provisional entity "Burkitt-like lymphoma with 11q aberration" (BLL, 11q) as lacking MYC rearrangement, but harboring the specific11q-gain/loss aberration.
|
29272887 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
DHL encompasses various histologies of lymphomas where the MYC oncogene and either BCL2 or BCL6 oncogenes are present concomitantly.
|
28711572 |
2017 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We compared communication networks within transformed B cells in different lymphomas affected by overexpressed MYC and conducted a meta-analysis concerning the association of MYC with tumor prognosis in different patient populations.
|
28375188 |
2017 |